I now have sufficient information from multiple authoritative sources to provide a complete answer.
Mechanism of D-Penicillamine
D-penicillamine (beta, beta-dimethylcysteine) is a degradation product of penicillin. Its free thiol (-SH) group is the key to nearly all of its pharmacological actions.
1. Copper (and Heavy Metal) Chelation
D-penicillamine is an effective chelator of copper, mercury, zinc, and lead. It binds these metals to form stable, water-soluble complexes that are excreted in the urine. This is its primary mechanism in Wilson's disease (hepatolenticular degeneration), where impaired biliary copper excretion leads to toxic tissue deposition. Oral chelation increases urinary copper output and gradually depletes the body's copper burden.
- Urinary copper excretion (target 200-400 mcg/24 h) is used to monitor adequacy of dosing.
- It is less potent and selective than other chelators (e.g., CaNa2EDTA, dimercaprol), so it is not first-line for acute heavy metal poisoning - but its oral bioavailability (40-70%) makes it convenient for long-term outpatient therapy.
(Goodman & Gilman's Pharmacological Basis of Therapeutics)
2. Disulfide Exchange Reaction (Cystinuria)
In cystinuria, excess cystine precipitates in urine to form stones. D-penicillamine undergoes a disulfide exchange reaction with cystine:
Cystine + D-penicillamine → Cysteine-penicillamine mixed disulfide
This mixed disulfide is far more soluble than cystine itself, preventing stone formation. The reaction is:
Cys-S-S-Cys + D-Pen-SH → Cys-S-S-Pen + CysSH
Dose used: 30 mg/kg/day up to 2 g/day.
(Brenner & Rector's The Kidney)
3. Immunomodulation / Anti-Inflammatory Mechanism (Rheumatoid Arthritis)
The exact mechanism in RA is not fully understood, but the proposed mechanisms include:
- Restoration of cellular free thiols - D-penicillamine and other thiol agents (e.g., sodium aurothiomalate) restore intracellular reduced thiol levels, which modulates redox-sensitive inflammatory signaling
- Sequestration of reactive aldehydes that drive inflammatory damage
- Inhibition of T-lymphocyte function and reduction of immunoglobulin levels (especially IgM rheumatoid factor)
- Interference with collagen cross-linking - penicillamine cleaves disulfide bonds in collagen, reducing pathological fibrosis and collagen deposition in synovium
(Rheumatology, 2-Volume Set, Elsevier 2022; Goodman & Gilman's)
4. Pyridoxine (Vitamin B6) Antagonism
D-penicillamine forms a Schiff base complex with pyridoxal phosphate (the active form of B6), inactivating it. This explains why:
- Pyridoxine deficiency can occur with prolonged use
- Supplementation with 25-50 mg/day of pyridoxine is routinely advised
- Optic neuritis is a rare consequence of deficiency
(Dikshit Textbook of Forensic Medicine; Goodman & Gilman's)
Summary Table
| Clinical Use | Mechanism |
|---|
| Wilson's disease | Copper chelation → urinary copper excretion |
| Cystinuria | Disulfide exchange → soluble cysteine-penicillamine mixed disulfide |
| Heavy metal poisoning (Pb, Hg, Zn) | Metal chelation → urinary excretion |
| Rheumatoid arthritis (DMARD) | Thiol restoration, immune modulation, collagen cross-link inhibition |
| Scleroderma | Inhibition of collagen cross-linking |
Key Side Effects (Mechanistically Explained)
| Side Effect | Mechanism |
|---|
| Pyridoxine deficiency (optic neuritis, neuropathy) | Schiff base formation inactivates pyridoxal phosphate |
| Membranous nephropathy, proteinuria | Immune complex deposition |
| Pemphigoid, SLE-like syndrome | Immune dysregulation |
| Aplastic anemia, agranulocytosis | Bone marrow suppression |
| Myasthenia gravis (with chronic use) | Autoantibody induction |
| Cross-hypersensitivity with penicillin | Structural similarity |
(Goodman & Gilman's; Murray & Nadel's Textbook of Respiratory Medicine)